SG11201405323YA - Liver x receptor modulators - Google Patents

Liver x receptor modulators

Info

Publication number
SG11201405323YA
SG11201405323YA SG11201405323YA SG11201405323YA SG11201405323YA SG 11201405323Y A SG11201405323Y A SG 11201405323YA SG 11201405323Y A SG11201405323Y A SG 11201405323YA SG 11201405323Y A SG11201405323Y A SG 11201405323YA SG 11201405323Y A SG11201405323Y A SG 11201405323YA
Authority
SG
Singapore
Prior art keywords
liver
receptor modulators
modulators
receptor
Prior art date
Application number
SG11201405323YA
Inventor
Chengguo Dong
Yi Fan
Stephen Lotesta
Suresh B Singh
Colin Tice
Wei Zhao
Yajun Zheng
Linghang Zhuang
Katerina Leftheris
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of SG11201405323YA publication Critical patent/SG11201405323YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
SG11201405323YA 2012-03-16 2013-03-14 Liver x receptor modulators SG11201405323YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612063P 2012-03-16 2012-03-16
PCT/US2013/031250 WO2013138568A1 (en) 2012-03-16 2013-03-14 Liver x reception modulators

Publications (1)

Publication Number Publication Date
SG11201405323YA true SG11201405323YA (en) 2014-10-30

Family

ID=47997958

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405323YA SG11201405323YA (en) 2012-03-16 2013-03-14 Liver x receptor modulators

Country Status (28)

Country Link
US (5) US9073931B2 (en)
EP (1) EP2825542B1 (en)
JP (3) JP6114815B2 (en)
KR (1) KR102069913B1 (en)
CN (1) CN104203950B (en)
AU (1) AU2013232069B2 (en)
BR (1) BR112014022780A8 (en)
CA (1) CA2865639C (en)
CY (1) CY1118323T1 (en)
DK (1) DK2825542T3 (en)
EA (1) EA026431B1 (en)
ES (1) ES2607113T3 (en)
HK (1) HK1206332A1 (en)
HR (1) HRP20161690T1 (en)
HU (1) HUE030785T2 (en)
IL (2) IL234301A (en)
LT (1) LT2825542T (en)
ME (1) ME02660B (en)
MX (1) MX354820B (en)
NZ (1) NZ629189A (en)
PL (1) PL2825542T3 (en)
PT (1) PT2825542T (en)
RS (1) RS55532B1 (en)
SG (1) SG11201405323YA (en)
SI (1) SI2825542T1 (en)
SM (1) SMT201700009B (en)
WO (1) WO2013138568A1 (en)
ZA (1) ZA201406390B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2825541T3 (en) 2012-03-16 2016-10-03 Vitae Pharmaceuticals Inc LIVER-X-receptor modulators
BR112014022780A8 (en) * 2012-03-16 2021-06-15 Vitae Pharmaceuticals Inc liver x receptor modulator compound, pharmaceutical composition comprising it and its use
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
WO2015195922A1 (en) * 2014-06-19 2015-12-23 Vitae Pharmaceuticals, Inc. Compounds for use in treating acute coronary syndrome and related conditions
BR112017002260A2 (en) * 2014-08-07 2017-11-21 Vitae Pharmaceuticals Inc piperazine derivatives as liver receptor x modulators
WO2017083216A1 (en) * 2015-11-12 2017-05-18 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
SG11202010115RA (en) 2018-05-15 2020-11-27 Alkahest Inc Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
US20220127680A1 (en) * 2019-02-28 2022-04-28 The Rockefeller Universtiy Apoe genotyping in cancer prognostics and treatment
US20220257596A1 (en) 2019-07-15 2022-08-18 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
MX2022007164A (en) 2019-12-13 2022-09-12 Inspirna Inc Metal salts and uses thereof.

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748247A (en) 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
CA2074163A1 (en) 1990-01-22 1991-07-23 William Thomas Zimmerman Herbicidal sulfonylureas
EP0572863A1 (en) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag CNS pyrazinoindoles
DK0817627T3 (en) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitors of protein kinase C
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
AU3831495A (en) 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
AU721130B2 (en) 1996-06-28 2000-06-22 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2257937A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
FR2761073B1 (en) 1997-03-20 1999-04-23 Synthelabo PYRAZINO [1,2-A] INDOLE-1-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2761070B1 (en) 1997-03-20 1999-04-23 Synthelabo DIHYDROPYRAZINO [1,2-A] INDOLE-1-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
DE19802235A1 (en) 1998-01-22 1999-07-29 Bayer Ag New oxazolidinone derivatives useful as antibacterial agents for treating local or systemic infections in humans or animals
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
EP1177177B1 (en) 1999-05-06 2005-02-23 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (en) * 1999-08-03 2002-09-09 Novuspharma Spa 1,2-DIIDRO-1-OXO-PIRAZINO 1,2-A INDOL DERIVATIVES.
AU1189201A (en) 1999-10-22 2001-05-08 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
EP1248612B1 (en) 2000-01-06 2008-02-27 Merck Frosst Canada Ltd. Novel compounds and compositions as protease inhibitors
CA2417106C (en) 2000-07-31 2007-09-18 F. Hoffmann-La Roche Ag Piperazine derivatives
JP2005506280A (en) 2000-12-20 2005-03-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Aryl and aminoaryl substituted serotonin receptor agonists and antagonist ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
FR2829766A1 (en) 2001-09-14 2003-03-21 Lipha Composition useful in the treatment of pathologies associated with e.g. hyperglycemia, diabetes, dyslipidemia, obesity, arterial hypertension, neuropathies, and nephropathies, comprises oxamate derivatives
US7094895B2 (en) 2001-12-21 2006-08-22 King Pharmaceuticals Research & Development, Inc. Tyrosyl derivatives and their use as P2X7 receptor modulators
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (en) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituted dihydroquinazolines
EP1714961B1 (en) 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
WO2005097108A1 (en) 2004-04-08 2005-10-20 Novartis Ag Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
RU2266906C1 (en) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Anellated carbamoyl azaheterocycles, methods for their preparing (variants), pharmaceutical composition, focused library
ITMI20040874A1 (en) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori INDOLIC AND AZAINDOLIC DERIVATIVES WITH ANTI-TUMORAL ACTION
WO2005113526A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
JP4709849B2 (en) 2004-12-15 2011-06-29 エフ.ホフマン−ラ ロシュ アーゲー Bicyclic and tricyclic substituted phenylmethanones as glycine transporter I (GLYT-1) inhibitors for the treatment of Alzheimer's disease
WO2006072608A2 (en) 2005-01-03 2006-07-13 Universitá Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
KR100974967B1 (en) 2005-07-14 2010-08-09 에프. 호프만-라 로슈 아게 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
EP1926724A1 (en) 2005-09-21 2008-06-04 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP4882127B2 (en) * 2005-11-16 2012-02-22 株式会社ジェイテクト Position adjustment type steering device
JP2007137810A (en) * 2005-11-17 2007-06-07 Sankyo Co Ltd Medicine containing indole compound
US7579351B2 (en) 2005-12-09 2009-08-25 Hoffmann-La Roche Inc. Tricyclic amide derivatives
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (en) * 2006-02-03 2010-09-03 Sanofi Aventis TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE PATTERN, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
RU2318818C1 (en) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants)
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2008122115A1 (en) 2007-04-09 2008-10-16 Methylgene Inc. Inhibitors of histone deacetylase
MX2009013897A (en) 2007-06-25 2010-03-30 Neurogen Corp Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues.
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
CN101456863B (en) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Novel LXR agonist as well as preparation method and application thereof
BRPI0822239A2 (en) * 2007-12-21 2015-06-30 Wyeth Llc Pyrazolo [1,5-a] pyrimidine compound
WO2009093747A1 (en) 2008-01-22 2009-07-30 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
WO2009097515A2 (en) 2008-01-30 2009-08-06 Wyeth [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
BRPI1010649A2 (en) 2009-06-08 2016-06-07 Gruenenthal Gmbh substituted benzimidazoles, benzothiazoles and benzoxazoles.
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
MX2012002827A (en) 2009-09-11 2012-04-10 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof.
JP5643332B2 (en) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
KR101302474B1 (en) * 2012-02-20 2013-09-02 주식회사 케이씨씨 A sealing member having good impact resistance and non-inflammability for vacuum insulation panel
DK2825541T3 (en) * 2012-03-16 2016-10-03 Vitae Pharmaceuticals Inc LIVER-X-receptor modulators
BR112014022780A8 (en) * 2012-03-16 2021-06-15 Vitae Pharmaceuticals Inc liver x receptor modulator compound, pharmaceutical composition comprising it and its use

Also Published As

Publication number Publication date
CA2865639A1 (en) 2013-09-19
JP2019006813A (en) 2019-01-17
ZA201406390B (en) 2019-11-27
US9707232B2 (en) 2017-07-18
AU2013232069B2 (en) 2017-07-13
US20170007603A1 (en) 2017-01-12
JP2017128589A (en) 2017-07-27
US20150336963A1 (en) 2015-11-26
SI2825542T1 (en) 2017-01-31
BR112014022780A8 (en) 2021-06-15
US20200138812A1 (en) 2020-05-07
WO2013138568A1 (en) 2013-09-19
EP2825542A1 (en) 2015-01-21
US9073931B2 (en) 2015-07-07
MX2014011104A (en) 2014-12-05
CN104203950A (en) 2014-12-10
CN104203950B (en) 2016-08-24
HUE030785T2 (en) 2017-06-28
BR112014022780A2 (en) 2017-06-20
CY1118323T1 (en) 2017-06-28
JP2015514061A (en) 2015-05-18
EA201491610A1 (en) 2014-12-30
LT2825542T (en) 2016-12-27
SMT201700009B (en) 2017-03-08
KR20140135829A (en) 2014-11-26
WO2013138568A8 (en) 2014-08-28
MX354820B (en) 2018-03-21
US9416135B2 (en) 2016-08-16
IL234301A (en) 2017-09-28
EA026431B1 (en) 2017-04-28
RS55532B1 (en) 2017-05-31
ME02660B (en) 2017-06-20
US20180117041A1 (en) 2018-05-03
US20150065515A1 (en) 2015-03-05
HRP20161690T1 (en) 2017-02-24
DK2825542T3 (en) 2017-01-09
IL251897A0 (en) 2017-06-29
ES2607113T3 (en) 2017-03-29
NZ629189A (en) 2016-08-26
AU2013232069A1 (en) 2014-09-18
CA2865639C (en) 2020-12-22
KR102069913B1 (en) 2020-01-23
PT2825542T (en) 2016-12-20
HK1206332A1 (en) 2016-01-08
PL2825542T3 (en) 2017-05-31
JP6114815B2 (en) 2017-04-12
EP2825542B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
IL251897A0 (en) Liver x receptor modulators
GB201213700D0 (en) Receptor antagnists II
PL2663550T3 (en) Substituted benzoazepines as toll-like receptor modulators
PL2663555T4 (en) Substituted benzoazepines as toll-like receptor modulators
HK1206333A1 (en) Liver receptor modulators
GB201004739D0 (en) Receptor modulators
HK1208867A1 (en) Indolecarbonitriles as selective androgen receptor modulators
HK1209744A1 (en) Novel selective androgen receptor modulators
IL235557A0 (en) Gpr17 receptor modulators
GB201223053D0 (en) Receptor
HUE049728T2 (en) Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators
EP2922539A4 (en) Substituted isoquinolines as crth2 receptor modulators
GB2501462B (en) Structural fixing
GB201202526D0 (en) Structural fixing
GB201219451D0 (en) Tiling